Table 3.
Subgroup analyses of study location, the assay used to measure serum PTH and 25-OHD, and the AVS procedure.
| Item | Subgroup | N of studies | N of patients | MD (95% CI) | I2 | P-value for I2 | X2 |
|---|---|---|---|---|---|---|---|
| PA vs. EH | |||||||
| Serum calcium | Asian Europe |
3 5 |
416/293 267/459 |
-0.03 (-0.11, 0.05) -0.07 (-0.13, -0.02) |
88% 87% |
<0.01 <0.01 |
0.81 |
| Urine calcium | Asian* Europe |
2 5 |
398/276 273/293 |
0.77 (0.42, 1.13) 1.59 (1.39, 1.80) |
0% 40% |
0.87 0.15 |
15.19 |
| Serum PTH | 1. Asian Europe |
3 7 |
416/293 325/538 |
2.37 (1.14, 3.59) 2.05 (1.36, 2.75) |
88% 81% |
<0.01 <0.01 |
0.19 |
| 2. ECLIA ELISA CLIA RIA Mix |
3 1 2 3 1 |
282/448 42/63 260/137 99/109 58/74 |
2.20 (1.46, 2.94) 0.80 (0.32, 1.28) 2.74 (1.04, 4.43) 2.02 (1.12, 2.92) 2.93 (1.52, 4.34) |
55% - 70% 71% - |
0.11 - 0.07 0.03 - |
18.9 | |
| Serum 25-OHD | 1. Asian Europe |
3 4 |
416/293 257/439 |
-0.16 (-6.34, 4.21) -11.15 (-30.75, 8.45) |
76% 89% |
0.02 <0.01 |
0.95 |
| 2. ECLIA ECLA CLA |
1 2 4 |
156/156 260/137 257/439 |
2.07 (-2.52, 6.66) -2.81 (-9.29, 3.67) -11.15 (-30.75, 8.45) |
- 59% 89% |
- 0.12 <0.01 |
2.75 | |
| Before-treatment vs. After-treatment PA | |||||||
| Serum calcium | Asian Europe* |
2 7 |
378/378 264/264 |
-0.09 (-0.19, 0.01) -0.06 (-0.09, -0.04) |
92% 0% |
<0.01 0.56 |
0.26 |
| Urine calcium | Asian Europe* |
1 6 |
99/99 225/225 |
2.57 (1.96, 3.18) 1.46 (0.71, 2.20) |
- 36% |
- 0.17 |
5.16 |
| Serum PTH | 1. Asian Europe |
2 10 |
114/114 351/341 |
2.89 (-0.89, 6.68) 2.58 (1.60, 3.57) |
91% 91% |
<0.01 <0.01 |
0.01 |
| 2. ECLIA* CLA CLIA ELISA Mix RIA |
4 1 4 1 1 1 |
173/173 36/36 154/154 42/32 46/46 14/14 |
2.05 (1.42, 2.68) 0.62 (-0.30, 1.54) 3.83 (2.22, 5.44) 0.68 (0.10, 1.26) 4.09 (2.54, 5.64) 3.23 (1.75, 4.71) |
0% - 75% - - - |
0.97 - <0.01 - - - |
37.87 | |
| Serum 25-OHD | 1. Asian Europe* |
2 7 |
74/74 286/286 |
-12.16 (-30.01, 5.68) -3.51 (-7.51, 0.49) |
95% 0% |
<0.01 0.95 |
0.86 |
| 2. ELISA CLA* ECLIA ECLA RIA |
1 5 1 1 1 |
63/63 192/192 15/15 59/59 31/31 |
-3.24 (-9.45, 2.97) -3.60 (-9.64, 2.44) -3.09 (-8.65, 2.47) -21.30 (-27.27, -15.33) -4.00 (-14.45, 6.45) |
- 0% - - - |
- 0.81 - - - |
26.77 | |
| Unilateral vs. Bilateral PA | |||||||
| Serum calcium # | 1. Asian* Europe |
6 3 |
338/453 151/105 |
-0.01 (-0.01, 0.01) -0.04 (-0.06, -0.01) |
0% 44% |
0.64 0.17 |
3.38 |
| 2. With ACTH Without ACTH |
4 5 |
149/255 340/303 |
-0.02 (-0.04, 0.00) -0.01 (-0.03, 0.01) |
36% 11% |
0.19 0.34 |
1.11 | |
| Urine calcium | Asian* Europe |
2 2 |
199/199 81/81 |
0.09 (-0.37, 0.54) 0.06 (-2.66, 2.78) |
0% 85% |
0.47 <0.01 |
0 |
| Serum PTH | 1. Asian* Europe |
6 3 |
338/453 151/105 |
0.99 (0.46, 1.51) 0.81 (-0.50, 2.12) |
29% 83% |
0.22 <0.01 |
0.02 |
| 2. With ACTH* Without ACTH |
4 5 |
149/255 340/303 |
1.12 (-0.90, 3.14) 1.09 (-0.01, 2.19) |
0% 78% |
0.68 <0.01 |
0.19 | |
| 3. ECLIA* RIA CLIA Mix |
5 2 1 1 |
262/370 58/57 123/119 46/12 |
0.87 (0.34, 1.40) 0.32 (-1.47, 2.11) 1.52 (0.56, 2.48) 3.34 (1.08, 5.60) |
28% 73% - - |
0.23 0.05 - - |
5.94 | |
| Serum 25-OHD # | 1. Asian* Europe* |
3 3 |
222/218 151/105 |
-4.45 (-7.58, -1.33) -6.10 (-14.03, 1.82) |
0% 3% |
0.98 0.35 |
0.14 |
| 2. With ACTH* Without ACTH* |
2 4 |
93/74 280/249 |
-5.55 (-12.81,1.70) -4.51 (-7.68,-1.34) |
0% 0% |
0.58 0.60 |
0.07 | |
| 3. ECLIA CLA* ECLA Unknown |
1 3 1 1 |
76/80 151/105 123/119 23/19 |
-4.91 (-11.45, 1.63) -6.10 (-14.03, 1.82) -3.75 (-13.39, 5.89) 04.41 (-8.23, -0.59) |
- 3% - - |
- 0.35 - - |
0.18 | |
N, number; MD, mean difference; 95% CI, 95% Confidence Intervals; CLA, chemiluminescence assay; ECLA, electro-chemiluminescence assay; ECLIA, electro-chemiluminescence immunoassay; ELISA, enzyme linked immunosorbent assay; CLIA, chemiluminescent immunoassay; RIA, immunoradiometric assays; *I2<50% in subgroup analysis; # I2<50% before subgroup analysis.